Remy Gross - 01 Apr 2024 Form 4 Insider Report for AgeX Therapeutics, Inc. (SER)

Reporting relationship: Director
Issuer ticker: SER
Reported as of: 01 Apr 2024
Net transaction value: $0
SEC form: 4
Accepted by SEC: 03 Apr 2024, 20:55:12 UTC
Prior SEC filing: 03 Apr 2024
Source filing: View source filing
Reporting owner signature: /s/ Remy Gross

Filing notes and source

Key filing fact

Remy Gross filed Form 4 for AgeX Therapeutics, Inc. (SER) on 03 Apr 2024.

Key facts

This page summarizes Remy Gross's Form 4 filing for AgeX Therapeutics, Inc. (SER).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 03 Apr 2024, 20:55.

Change

Previous filing in this sequence was filed on 03 Apr 2024.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

SER transaction Derivative

Stock Option (right to buy)

Award

Transaction value: $0
Shares: +40,000
Change %: +34%
Price: $0.000000
Shares after: 157,219
Date: 01 Apr 2024
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 40,000
Exercise price: $11.83
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

The stock options vest in three equal installments on April 1, 2025, April 1, 2026 and April 1, 2027, subject to the Reporting Person's continued service to the Issuer through the applicable vesting dates.